Entera Bio Ltd. (ENTX)

NCM – Real Time Price. Currency in USD

1.25

+0.08 (6.84%)

At close: May 12, 2026, 4:00 PM EDT

1.25

-0.00 (-0.40%)

Pre-market: May 13, 2026, 8:13 AM EDT

08.05.2026

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ASBMR

29.04.2026

Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know

Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

20.04.2026

Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript

20.04.2026

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

In a virtual Key Opinion Leader (KOL) roundtable hosted today, Entera Bio (Nasdaq: ENTX) convened globally recognized authorities in osteoporosis and women's health to discuss the current osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 - being developed as the first and only oral anabolic (bone-forming) tablet for osteoporosis.

14.04.2026

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced it will host a virtual Key Opinion Leader (KOL) webinar focused on the osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 (oral PTH (1-34) tablet), on Monday, April 20, 2026 at 11:00 AM Eastern Time.

06.04.2026

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

MIAMI, April 6, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd.

02.04.2026

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered into a securities purchase agreement for a private placement (the “Private Placement”) led by funds affiliated with BVF Partners L.P. (“BVF”).

Videos

No Data

There is no data to display

Press releases

08.05.2026

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

20.04.2026

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

14.04.2026

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

06.04.2026

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

MIAMI, April 6, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd.

Entera Bio Ltd. (ENTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Entera Bio Ltd. (ENTX)

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know

Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

Videos

No Data

Press releases

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know

Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

Videos

No Data

Press releases

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

Search stocks

Entera Bio Ltd. (ENTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Entera Bio Ltd. (ENTX)

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know

Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

Videos

No Data

Press releases

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know

Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

Videos

No Data

Press releases

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners